



## Research article

## ANTI-OBESITY EFFECT OF DEXTROMETHORPHAN IN HIGH FAT DIET INDUCED OBESE RATS

Shah Palak A\*, Paregi Kanti, Patel Nimisha K, Deshpande Shrikalp S

*Department of Pharmacology, K. B. Institute of Pharmaceutical Education and Research, Kadi Sarva Vishwavidyalaya, Gandhinagar, Gujarat, India*

## Abstract

**Background:** Obesity is linked to significant comorbidities. Treatment options for obesity include only few drugs. Several hormones and receptors play key role in pathogenesis of obesity like NMDA, PPAR-gamma, leptin, pro-opiomelanocortin (POMC) and others.

**Objective:** To evaluate the anti-obesity effect of Dextromethorphan (DXM) in high fat diet (HFD) induced experimental obesity in rats.

**Material and Methods:** Male Wistar albino rats (BW- 250-350 grams) were divided into 5 groups. Group 1 (Normal control) was fed with standard pellets. The remaining groups were fed with High Fat Diet (HFD) to induce obesity. Group 2 (HFD) served as disease control. Group 3 (standard), Group 4 (DXM-P) and Group 5 (DXM-T) received orlistat (10 mg/kg, day 49 to 84), dextromethorphan (DXM) (15 mg/kg, day 0 to 84) and DXM (15 mg/kg, day 49 to 84) respectively. All the drugs were administered orally. Food intake (daily), water intake (daily) and body weight (weekly) were measured. Serum cholesterol (TC), Serum triglyceride (TG), HDL and LDL; OGTT, BMI, white adipose tissue (WAT) mass were measured.


**Results:** No significant difference was observed in food intake, BMI, TC, LDL and HDL between disease and treatment groups. BMI was significantly increased in HFD group and decreased in orlistat and DXM-P group. Blood glucose and WAT mass were significantly decreased in all treatment groups as compared to HFD control.

**Conclusion:** Administration of DXM in both the groups improved body weight, BMI (only DEX-P), WAT mass, glucose tolerance and serum TG. Dextromethorphan can be further studied for further development in treatment of obesity.

**Key words:** Obesity, Dextromethorphan, Orlistat, BMI, Adipose tissue

**Article Info:** Received 28 Aug 2023; Review Completed 16 Sept 2023; Accepted 04 Oct 2023

Revised and resubmitted 15 Jul 2024; Accepted 22 Aug 2024



## Cite this article as:

Shah P, Paregi K, Patel N, Deshpande S. Anti-obesity effect of dextromethorphan in high fat diet induced obesity in rats. KSV Journal of Pharmacy and Health Sciences 2024;1(1):31-36

Available from: <https://www.ksvjphs.com/index.php/journal/issue/current>

\*Corresponding Author

## Introduction

Obesity is serious health issue causing 2.8 M avoidable deaths each year. Meaning of obesity is abnormal or excessive buildup of fat in body which possess a health concern. Body mass index (BMI) is more than 30 is called Obesity [1].

Comorbidities associated with obesity include high risk of hypertension, hypercholesteremia, gallbladder dyspnea, cancers, etc. Genetics, nutrition, imbalance between calory intake and exercise, eating habits, sedentary lifestyle, sleep, and stress contributes to excess weight and ultimately obesity. Mutations in FTO gene, hormonal disorders e. g hypothyroidism, insulin tolerance, menopause and polycystic ovary syndrome (PCOS), drugs (antidepressants, anticonvulsant, contraceptives, antipsychotics, and corticosteroids) may induce weight gain [2,3].

In Indian people obesity is higher than the world average. As per report, in Indian women, 'in year between 1998 and 2015, the prevalence of overweight and obesity increased from 8.4 to 15.5% and 2.2 to 5.1 % respectively'. While global trends study assessed that at the end of 2030, almost 27.8% of all Indians would be overweight and 5 % would be obese [4]. The pharmacological treatment obesity includes FDA approved drugs. The impact of these drugs in relation to the costs and benefits of therapy is always a topic for discussion [5,6].

Several inflammatory mediators are associated with obesity. Adipocytes secrete inflammatory adipokines playing critical roles in inflammation [2]. Disturbances in gut microflora can lead to inflammation of the intestinal lining and ultimately obesity [7]. Apart from this, peptide mediators, central and autonomic neurotransmitters, and hormones are also key players in orexigenic and anorexigenic pathways.

Some examples are Neuropeptide-Y, insulin, leptin, Proopio-melanocortin, etc. [8]. Two populations of neurons have mutually antagonistic functions found in arcuate hypothalamic nuclei (Arc) that control appetite and body weight by increase in food intake with the activation of neuropeptide-Y (NPY)/agouti-related protein (AgRP) containing neurons, while appetite was suppressed by POMC neurons activation. Majority of POMC containing neurons in Arc nuclei contains functions as an anorexigenic signal molecule.

Leptin induced stimulation of POMC neurons leads to production of  $\alpha$ -MSH, is the critical anorexigenic peptide. This centers further mediate higher centers

such as limbic systems to further regulate the energy intake- energy expenditure homeostasis [9,10]. Activation of NMDA receptors NMDARs mediate the leptin action and modulate pancreatic beta-cell activity through AMP-activated protein kinase (AMPK) signaling ultimately improving insulin sensitivity [11]. Dextromethorphan (DXM) is weak Sigma- 1 opioid receptor agonis widely used as an antitussive drug.

The metabolite of DXM, 3-hydroxymorphinan, enhances mitochondrial biogenesis, browning and lipid accumulation in adipocytes via AMP-activated protein kinase dependent pathway. Here activation of AMPK pathway by 3-hydroxymorphinan may be the potential target for obesity [12]. From the literature review, we tried to find out possible anti-obesity effect of dextromethorphan in experimental obesity in rats by using high fat diet.

## Materials and methods

**Drugs and Chemicals:** Dextromethorphan hydrobromide was gifted from Lincoln pharma, Ahmedabad). Orlistat (Eris life science limited); cholesterol and triglyceride kit (Span diagnostics Pvt Ltd., Surat, Gujrat, India) were purchased.

**Ethics Approval:** The project was sanctioned and accepted by the CPCSEA and Institutional Animal Ethics Committee and provide project no. KBIPER/2022/646.

**Animals and study groups:** Healthy male Wistar albino rats (body weight 250 to 350 gms) were randomized based on body weight before the experiment started (on day 0). Animals were housed in polypropylene cage in controlled environment with a 22 °C temperature, 55± 5% humidity, and a 12 hr/12 hr alternated light and dark cycle.

Animals had unlimited used to a standard laboratory feed procured from Pranav Agro, Baroda and water *ad libitum*. Animals were divided into five groups and each containing six animals. Normal control as Group 1 animals received standard diet. All other group of animals except Normal Control group were fed with high fat diet diet for 84 days to induce obesity [13]. Disease control (HFD control-Group 2) animals received no treatment. Group 3 received orlistat (10 mg/kg, day 49 to 84).

Animals in Group 4 (DEX-P) and group 5 (DXM-T) were administered dextromethorphan (15 mg/kg) for prophylaxis (day 1 to 84) and as treatment (day 1 to 84) respectively. All the drugs were administered once in a day via per oral route.

**Table 1: Study groups and treatments**

Group No.	Group	Treatment	Duration
1	Control	Normal diet + vehicle	Day 1 to 84
2	Disease control	HFD + vehicle	Day 1 to 84
3	STD 1	HFD + orlistat (10 mg/kg, p.o, oid)	Day 49 to 84
4	Test 1 (DEX-P)	HFD + Dextromethorphan (15 mg/kg, p.o, oid)	Day 1 to 84
5	Test 2 (DXM-T)	HFD + Dextromethorphan (15 mg/kg, p.o, oid)	Day 49 to 84


**Parameters:** Food intake (daily) and body weight (weekly) were measured from day 1 to 84. Serum total cholesterol (TC), serum triglyceride (TG), LDL and HDL (on day 28, 49, 63, 84) was measured. By using glucometer OGTT test was performed on day 35 and 70. On day 84, all the animals were sacrificed using isoflurane inhalation anesthesia. Epididymal white adipose tissue (WAT) was isolated and weighed. BMI was calculated on day 0 and 84.

**Statistical Analysis:** Data was expressed as the mean  $\pm$  SEM. One-way ANOVA multiple comparison test was done by post hoc Tuckey test was performed for quantitative parameters (Lipid parameters, body weight, OGTT, WAT mass). For the statistical calculation of food intake, Two-way ANOVA followed by 'Bonferroni test'. In this case  $p < 0.05$  was considered as statistical significance. Statistical software: Graph-pad Prism version 9.0 (free trial version)

## Results

### Percentage change in Body weight:


Animals in HFD group ( $20.5 \pm 4.3$ ,  $23.6 \pm 4.8$ ,  $24.13 \pm 4.9$ ,  $30.3 \pm 5.7$ ,  $34.2 \pm 4.9$ ,  $36.1 \pm 4.6$ ,  $38.3 \pm 4.2$ ,  $34.0 \pm 4.3$ ) showed significant changes in the meaning of increase in percentage body weight as compared to normal control group ( $5.5 \pm 0.9$ ,  $5.9 \pm 1.2$ ,  $6.7 \pm 1.3$ ,  $7.3 \pm 1.1$ ,  $9.3 \pm 1.9$ ,  $16.9 \pm 5.7$ ,  $18.82 \pm 3.4$ ) on day 35, 42, 49, 56, 63, 70, 77 and 84 respectively. Treatment with DXM-P significantly changed (decreased) percentage body weight on day 49, 63 and 84 ( $20.9 \pm 0.9$ ,  $20.4 \pm 1.9$ ,  $21.9 \pm 1.5$ ) as compared to HFD group. Orlistat treatment and DXM-T significantly decreased percentage body weight ( $25.5 \pm 1.9$ ,  $28.2 \pm 0.54$ ) and ( $28.7 \pm 3.4$ ,  $32.8 \pm 2.9$ ) on day 63 and 84 as compared to HFD group respectively (**Fig. 1**).

**Figure 1: Effect of DXM on Percentage change in Body weight**

\*Indicates significant difference from control group;  
#Indicates significant difference from HFD group  
( $p < 0.05$ , One way ANOVA followed by Tukey's test)

### Food intake

Intake was expressed as cumulative food intake gm/animal/day. There was no significant difference in food intake between HFD group and NC group was observed (**Fig. 2**).

**Figure 2: Effect of DXM on Food intake**


$p < 0.05$ , Two-way ANOVA followed by Bonferroni test

### BMI


BMI was significantly higher in HFD group ( $0.59 \pm 0.01$ ) as compared to NC group ( $0.59 \pm 0.01$ ) on day 84. Orlistat ( $0.72 \pm 0.016$ ), DXM-P ( $0.64 \pm 0.03$ ) showed significantly decreased BMI as compared to HFD group. Treatment group DXM-T did not show any significant change in BMI on day 84 (**Fig. 3**).

### Oral glucose tolerance test (Day 35)

Blood glucose was significantly higher in HFD group ( $133.2 \pm 2.2$ ) as compared to NC group ( $115 \pm 3.4$ ) (at 60 min). Significant decrease in blood glucose was found in DXM-P ( $128 \pm 4.2$ ) as compared to HFD group (at 60 min) (**Fig. 4**).


**Figure 3: Effect of DXM on Body Mass Index (BMI)**

\*Indicates significant difference from control group;  
 #Indicates significant difference from HFD group  
 (p<0.05, One way ANOVA followed by Tukey's test)

**Figure 4: Oral glucose tolerance test (Day 35)****Oral glucose tolerance test (Day 70)**

Blood glucose was significantly higher in HFD group ( $145.2 \pm 2.2$ ,  $170 \pm 3.4$ ) as compared to NC group ( $100 \pm 3.3$ ,  $110 \pm 2.6$ ) (at 60 and 90 min). The significant difference in blood glucose was found in orlistat ( $145.2 \pm 2.4$ ), DXM-P ( $138.7 \pm 3.2$ ), DXM-T ( $159.3 \pm 4.2$ ) as compared to HFD group (at 60 min) (Fig. 5).


**Effect of DXM on serum TC, HDL, LDL and TG**  
 No significant difference was observed in serum TC, HDL, and LDL between HFD group and NC group. Serum triglyceride was significantly increased in HFD group ( $175.7 \pm 14.2$ ,  $189.9 \pm 10.6$ ) as compared to NC group ( $143 \pm 1.6$ ,  $141.3 \pm 7.4$ ) on day 63 and 84 respectively. Orlistat ( $147.6 \pm 13.07$ ), DXM-P ( $143.2 \pm 11.6$ ) and DXM-T ( $163 \pm 12.8$ ) significantly decreased serum TG level compared to HFD on day 84 respectively (Table 2).

**Figure 5: Oral glucose tolerance test (Day 70)**

\*Here this sign indicates significant difference from control group; #This sign indicates significant difference from HFD group if p<0.05, then one way ANOVA followed by Tukey's test.

**White adipose tissue (WAT) mass**

Animals in HFD group ( $13.7 \pm 0.96$ ) had significantly higher WAT mass as compared to NC group ( $2.4 \pm 0.12$ ) on day 84. Animals treated with Orlistat ( $0.72 \pm 0.02$ ), DXM-P ( $0.64 \pm 0.035$ ), DXM-T ( $0.71 \pm 0.02$ ) data showed significantly lower WAT mass as compared to HFD group as shown in figure 6.

**Figure 6: Effect of DXM on Mass of white adipose tissue (WAT)**

\*Indicates significant difference from control group;  
 #Indicates significant difference from HFD group where p<0.05, by using one way ANOVA followed by Tukey's test.

**Table 2: Effect of DXM on Serum TC, HDL, LDL and TG**

Lipid Parameters	DAY	NC	HFD	Orlistat	DXM-P	DXM-T
<b>TC (mg/dL)</b>	28	115.1±3.6	122.4±3.6	117.4± 5.7	16.2 ± 19.8	128.3 ± 5.8
	49	131.4±16.3	131.3±16.3	104.0±10.5	116.3±8.5	119.2±8.9
	63	123.9± 6.8	123.9±6.8	111.1 ± 4.0	122.9 ± 9.7	132.5 ± 9.7
	84	43.21 ± 5.3	143.2±5.3	115.4± 7.0	128.27 ± 5.8	120.5 ± 8.0
<b>HDL (mg/dL)</b>	28	45.7±0.97	43.6±1.3	43.08±2.2	44.51±2.6	41.93±1.3
	49	46.6±2.3	40.1±1.2	41.18±1.3	47.83±1.8	40.91±0.3
	63	44.7±0.24	40.2±1.2	43.28±1.4	47.83±1.9	44.81±1.0
	84	43.3±3.4	40.51±3.1	39.92±1.5	41.38±1.6	42.04±1.2
<b>LDL (mg/dL)</b>	28	45.6±4.5	54.1±5.4	48.3±48.1	48.1±19.8	56.7±5.3
	49	42.2±2.2	61.0±16.7	31.5±47.1	47.1±7.9	46.1±8.7
	63	38.2±2.9	45.3±6.5	37.1±45.6	45.6±7.8	58.6±6.8
	84	43.3±3.4	64.7±4.1	45.9±58.2	58.24±5.6	45.7±7.5
<b>TG (mg/dL)</b>	28	120.8 ± 1.8	123.5 ± 8.5	129.8 ± 9.6	118.0 ± 3.9	123.37 ± 5.2
	49	131.1±2.2	151.3±6.2	156.8±9.1	136.4±9.1	123.4 ± 5.3
	63	143.0±1.6	175.7 ±14.2*	153.7 ±11.2	147± 13.4	145.3 ± 10.1
	84	141.3±7.4	189.9 ±10.5*	147.6± 13.1 <sup>#</sup>	143.2 ±11.6 <sup>#</sup>	164.3 ±12.8 <sup>#</sup>

\*Indicates significant difference from the control group

<sup>#</sup>Indicates significant difference from HFD group (p<0.05, One way ANOVA followed by Tukey's test)

## Discussion

Administration of HFD for 84 days induced obesity in HFD rats. This was demonstrated by increase body weight and BMI. Body mass index is a widely used surrogate marker of obesity. Treatment with orlistat, DXM- P and DXM-T in rats did not show increase in % body weight as compared to HFD group. In the current study, feeding HFD for 84 days resulted in considerably higher serum TG levels in the HFD rats, but there was no significant change in TC, LDL and HDL levels. No significant difference was observed in orlistat group, DXM-P and DXM-T group. Administration of glucose during OGTT in HFD group significantly increased glucose level on day 35 (at 60 minute) and on day 70 (at 60 and 90 minute), indicating glucose intolerance. Administration of dextromethorphan significantly improved glucose tolerance on day 70 when administered from day 49. Prophylactic administration of dextromethorphan improved glucose tolerance on both day 35 and 70. Obesity is frequently associated with glucose intolerance indicated as impaired OGTT [14]. BMI was measured on day 0 and 84. HFD treated rats showed significantly higher BMI compared to control animals. Orlistat and prophylactic administration of dextromethorphan in DXM-P group significantly decreased BMI. Epididymal WAT mass of HFD treated animals was significantly higher than normal animals. All animals receiving Orlistat, DXM-P and

DXM-T showed significantly lower WAT mass value as compared to HFD animals. In our study, DEX-P and DEX-T did not alter lipid parameters except serum TG. This can be justified by numerous studies that show obese people may not have always hypercholesteremia. The prevalence of glucose intolerance was found to be higher in children and adolescents with severe obesity [15]. Obesity is strongly correlated with insulin impairment and glucose intolerance [16]. Our study also showed the same. The obese rats showed impaired glucose tolerance. Dextromethorphan treatment improved glucose tolerance probably due to improving insulin-leptin sensitivity at central level.

Hypothalamic POMC neurons play important role in obesity [17]. Melanocortin (MC), POMC and Agouti-related peptide (AgRP) are closely linked in pathogenesis of obesity. As per literature agouti-related peptide (AgRP) is an inverse agonist of MC3R and MC4R. Early-onset severe obesity and monogenic forms of obesity are linked to MC4R mutations that are responsible for melanocortin-dependent control of feeding [18]. Mutations of POMC are associated with obesity phenotypes. As per literature, that mouse knockouts for POMC, MC4R and MC3R stated as obese phenotype. In addition to this,  $\alpha$ -melanocyte-stimulating hormone ( $\alpha$ -MSH) released by POMC neurons, binds to MC4R expressed by MC4R



neurons to the paraventricular nucleus (PVN). This ultimately results into decreased energy intake [19]. Dextromethorphan by its action on POMC, AgRP/NPY, and MC4R neurons pathway, improves body weight and fat deposition.

### Conclusion

Dextromethorphan decreases the body weight, BMI and adipose tissue mass; improves glucose tolerance in obese rats demonstrating its promising role in obesity.

### Financial disclosure statement

Study was supported by KBIPER, Gandhinagar

### Conflicts of interest

None declared.

### References

1. Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. *Nutr Today*. 2015; 50(3):117-128. doi: 10.1097/NT.000000000000092.
2. Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The Role of Adipokines in Inflammatory Mechanisms of Obesity. *Int J Mol Sci*. 2022;23(23):14982. doi: 10.3390/ijms232314982.
3. Wright SM, Aronne LJ. Causes of obesity. *Abdom Imaging*. 2012; 37(5): 730-2. doi: 10.1007/s00261-012-9862-x.
4. Lobstein T, Jewell J. What is a "high" prevalence of obesity? Two rapid reviews and a proposed set of thresholds for classifying prevalence levels. *Obes Rev*. 2022; 23(2): e13363. doi: 10.1111/obr.13363.
5. Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R and Mantzorosc CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. *eClinical Medicine*. 2023; 58: 101882. doi: <https://doi.org/10.1016/j.eclinm.2023.10188>.
6. Cornier MA. A review of current guidelines for the treatment of obesity. *Am J Manag Care*. 2022; 28 (15 Suppl): S288-S296. doi: 10.37765/ajmc.2022.89292.
7. Gérard, P. Gut microbiota and obesity. *Cell Mol Life Sci*. 2016; 73: 147–162. doi: <https://doi.org/10.1007/s00018-015-2061-5>.
8. Oussaada SM, van Galen KA, Cooiman MI, Kleinendorst L, Hazebroek EJ, van Haelst MM, Ter Horst KW, Serlie MJ. The pathogenesis of obesity. *Metabolism*. 2019; 92: 26-36. doi: 10.1016/j.metabol.2018.12.012.
9. Farhadipour M, Depoortere I. The Function of Gastrointestinal Hormones in Obesity- Implications for the Regulation of Energy Intake. *Nutrients*. 2021; 13(6): 1839. doi: 10.3390/nu13061839.
10. Wren AM. Gut and hormones and obesity. *Front Horm Res*. 2008; 36:165-181. doi: 10.1159/000115364.
11. Wu Y, Fortin DA, Cochrane VA, Chen PC, Shyng SL. NMDA receptors mediate leptin signaling and regulate potassium channel trafficking in pancreatic  $\beta$ -cells. *J Biol Chem*. 2017 Sep 15;292(37):15512-15524. doi: 10.1074/jbc.M117.802249.
12. Jung TW, Hwang EJ, Pyun DH, Kim TJ, Lee HJ, Abd El-Aty AM, Bang JS, Kim HC, Jeong JH. 3-hydroxymorphinan enhances mitochondrial biogenesis and adipocyte browning through AMPK-dependent pathway. *Biochem Biophys Res Commun*. 2021; 577:17-23. doi: 10.1016/j.bbrc.2021.08.083.
13. Woods SC, Seeley RJ, Rushing PA, D'Alessio D, Tso P. A controlled high-fat diet induces an obese syndrome in rats. *J Nutr*. 2003; 133(4):1081-7. doi: 10.1093/jn/133.4.1081.
14. Saaristo TE, Barengo NC, Korpi-Hyövälti E, Oksa H, Puolijoki H, Saltevo JT, Vanhala M, Sundvall J, Saarikoski L, Peltonen M, Tuomilehto J. High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population. *BMC Public Health*. 2008; 8:423. doi: 10.1186/1471-2458-8-423.
15. Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. *N Engl J Med*. 2002; 346(11):802-10. doi: 10.1056/NEJMoa012578.
16. Gerlini R, Berti L, Darr J, Lassi M, Brandmaier S, Fritsche L, Scheid F, Böhm A, Königsrainer A, Grallert H, Häring HU, Hrabě de Angelis M, Staiger H, Teperino R. Glucose tolerance and insulin sensitivity define adipocyte transcriptional programs in human obesity. *Mol Metab*. 2018; 18:42-50. doi: 10.1016/j.molmet.2018.09.004.
17. Millington GW. The role of proopiomelanocortin (POMC) neurones in feeding behaviour. *Nutr Metab (Lond)*. 2007; 4:18. doi: 10.1186/1743-7075-4-18.
18. Jais A, Brüning JC. Arcuate Nucleus-Dependent Regulation of Metabolism-Pathways to Obesity and Diabetes Mellitus. *Endocr Rev*. 2022 Mar 9;43(2):314-328. doi: 10.1210/endrev/bnab025.
19. Baldini G, Phelan KD. The melanocortin pathway and control of appetite-progress and therapeutic implications. *J Endocrinol*. 2019; 241(1): R1-R33. doi: 10.1530/JOE-18-0596.